Targeting hard-to-treat cancers
At Ryvu, we focus on treating cancers that are difficult to manage and require innovative therapeutic approaches. Our research targets diseases like acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (HR-MDS), low-risk MDS, myelofibrosis and diffuse large B-cell lymphoma (DLBCL). We are dedicated to developing therapies that address the unique challenges of these conditions, aiming to improve patient outcomes and quality of life.

Our Clinical Trials
We are committed to improving the quality of life for cancer patients. We recognize the difficulties faced by patients and their caregivers, so we are here to provide support and information that can help you and your loved ones.
Ryvu is currently conducting clinical trials for the treatment of patients with acute myeloid leukemia (AML), high- and low-risk myelodysplastic syndromes (HR-MDS, MDS), myelofibrosis, and DLBCL.
Healthcare Providers
Download clinical brochureFor more detailed information on our clinical trials, please refer to the resources below and our comprehensive clinical trials brochure.
Patients
Before considering participation in one of our clinical trials, we recommend discussing your options with your physician to understand if it’s the right choice for you, including the potential risks and benefits. Additional resources can be found in the links below.
Ongoing & future trials
As a Sponsor of a clinical trial, we are unable to process patients’ personal data, especially medical data. All decisions regarding eligibility for participation in the study are made by independent research centers. It results from applicable legal regulations, including Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC and Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). The best step will be to contact the research center conducting the clinical trial directly.
RIVER-81
NOW RECRUITINGMore detailsAML
RVU120 + venetoclaxJASPIS-01
NOW RECRUITINGMore detailsDLBCL
Dapolsertib (PIM/FLT3) + glofitamabREMARK
RECRUITMENT ENDEDMore detailsLow Risk MDS
RVU120POTAMI-61
RECRUITMENT ENDEDMore detailsMyelofibrosis
RVU120 + ruxolitinib
Study results are intended to satisfy public disclosure commitments and shall not be used for any other purpose. This information is not intended to promote or otherwise make any claims for any investigational or marketed products.

Online resources
Explore our Online Resources for in-depth scientific information on Leukemia, Lymphoma, and other cancers.
Contact
FOR MEDICAL PROFFESIONALS & INVESTIGATORS
If you are a medical professional, an investigator for a RYVU trial, or would like information about becoming an investigator, please contact us at [email protected] or use contact form.
